NYSE:EW

Edwards Lifesciences - EW Stock Forecast, Price & News

$82.63

-1.20 (-1.43%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $82.50
▼
$85.84
50-Day Range: $82.37
▼
$107.29
52-Week Range: $81.87
▼
$131.73

Volume: 2.73 million shs
Average Volume: 2.68 million shs
Market Capitalization: $51.23 billion

P/E Ratio: 35.77
Dividend Yield: N/A
Price Target: $125.50

Edwards Lifesciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.85 Rating Score
Upside/Downside: 51.9% Upside
$125.50 Price Target
Short Interest: Healthy
1.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.95
Upright™ Environmental Score
News Sentiment: 1.14
Based on 3 Articles This Week
Insider Trading: Selling Shares
$8.22 M Sold Last Quarter
Proj. Earnings Growth: 7.97%
From $2.51 to $2.71 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

91st out of 1,095 stocks

Surgical Appliances & Supplies Industry

6th out of 24 stocks

3.4

Analyst's Opinion

Consensus Rating
Edwards Lifesciences has received a consensus rating of Buy. The company's average rating score is 2.85, and is based on 17 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $125.50, Edwards Lifesciences has a forecasted upside of 51.9% from its current price of $82.63.
Amount of Analyst Coverage
Edwards Lifesciences has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.07% of the float of Edwards Lifesciences has been sold short.
Short Interest Ratio / Days to Cover
Edwards Lifesciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Edwards Lifesciences has recently increased by 77.72%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Edwards Lifesciences does not currently pay a dividend.
Dividend Growth
Edwards Lifesciences does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Edwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.
Environmental Sustainability
The Environmental Impact score for Edwards Lifesciences is -0.95.

2.3

News and Social Media Coverage

News Sentiment
Edwards Lifesciences has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Edwards Lifesciences this week, compared to 5 articles on an average week.
Search Interest
Only 6 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
Only 12 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,223,839.00 in company stock.
Percentage Held by Insiders
Only 1.29% of the stock of Edwards Lifesciences is held by insiders.
Percentage Held by Institutions
81.33% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Edwards Lifesciences are expected to grow by 7.97% in the coming year, from $2.51 to $2.71 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Edwards Lifesciences is 35.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.72.
Price to Earnings Ratio vs. Sector
The P/E ratio of Edwards Lifesciences is 35.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 123.02.
Price to Earnings Growth Ratio
Edwards Lifesciences has a PEG Ratio of 2.48. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Edwards Lifesciences has a P/B Ratio of 8.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Stock News Headlines

September 30, 2022 | finance.yahoo.com

12 Best Medical Technology Stocks to Buy

September 22, 2022 | markets.businessinsider.com

What 8 Analyst Ratings Have To Say About Edwards Lifesciences

September 21, 2022 | nasdaq.com

Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?

September 17, 2022 | wsj.com

Abbott Heart Valve Device Faces Competition

September 17, 2022 | finance.yahoo.com

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

September 17, 2022 | finance.yahoo.com

Abbott Faces Competition From Heart Valve Device Cleared by FDA

September 16, 2022 | nasdaq.com

First Week of EW May 2023 Options Trading

September 15, 2022 | nasdaq.com

Edwards Lifesciences Gains On FDA Approval For Pascal Precision Trancatheter Valve Repair System

September 15, 2022 | finance.yahoo.com

FDA Approves Edwards Lifesciences' PASCAL Precision Transcatheter Valve Repair System For Most Frequent Cardiovascular Disorder

September 15, 2022 | finance.yahoo.com

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

September 13, 2022 | finance.yahoo.com

Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve

September 13, 2022 | finance.yahoo.com

Edwards Lifesciences Sends Positive Signals but Merits Wait-and-See Approach

September 12, 2022 | nz.finance.yahoo.com

Great week for Edwards Lifesciences Corporation (NYSE:EW) institutional investors after losing 20% over the previous year

September 7, 2022 | finance.yahoo.com

12 Best Medical Device Stocks To Buy Now

September 1, 2022 | seekingalpha.com

EW Edwards Lifesciences Corporation

August 17, 2022 | fool.com

Edwards Lifesciences (NYSE: EW)

August 17, 2022 | finance.yahoo.com

At US$102, Is Edwards Lifesciences Corporation (NYSE:EW) Worth Looking At Closely?

August 17, 2022 | finance.yahoo.com

EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK

August 15, 2022 | seekingalpha.com

Edwards Lifesciences: Stretched Valuation And Bearish Resistance In Play

August 5, 2022 | msn.com

Edwards Lifesciences Whale Trades Spotted

July 29, 2022 | nasdaq.com

Notable Friday Option Activity: EW, PYPL, ETSY

July 29, 2022 | investing.com

Edwards Lifesciences Down on Earnings Miss as Hospital Staffing 'Remains Uncertain'

July 29, 2022 | finance.yahoo.com

Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up

July 29, 2022 | fool.com

Edwards Lifesciences (EW) Q2 2022 Earnings Call Transcript

July 29, 2022 | fool.com

Edwards Lifesciences (EW) Q2 2022 Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Company Calendar

Last Earnings: 7/28/2022
Today: 10/02/2022
Next Earnings (Estimated): 10/26/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical appliances & supplies
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NYSE:EW
CUSIP: 28176E10
CIK: 1099800
Web: www.edwards.com
Phone: (949) 250-2500
Fax: 949-250-2525
Employees: 15,700
Year Founded: 1958

Price Target and Rating

Average Stock Price Forecast: $125.50
High Stock Price Forecast: $144.00
Low Stock Price Forecast: $106.00
Forecasted Upside/Downside: +51.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.85
Research Coverage: 20 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.31
Trailing P/E Ratio: 35.77
Forward P/E Ratio: 32.92
P/E Growth: 2.48
Net Income: $1.50 billion
Net Margins: 27.18%
Pretax Margin: 31.15%
Return on Equity: 24.77%
Return on Assets: 17.12%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 3.37
Quick Ratio: 2.60

Sales & Book Value

Annual Sales: $5.23 billion
Price / Sales: 9.79
Cash Flow: $2.43 per share
Price / Cash Flow: 34.01
Book Value: $9.35 per share
Price / Book: 8.84

Miscellaneous

Outstanding Shares: 619,940,000
Free Float: 611,946,000
Market Cap: $51.23 billion
Optionable: Optionable
Beta: 1.14

Social Links

Key Executives

Mr. Michael A. Mussallem (Age 69)
Chairman & CEO
Comp: $2.88M

Mr. Scott B. Ullem (Age 55)
Corp. VP & CFO
Comp: $1.32M

Mr. Donald E. Bobo Jr. (Age 60)
Corp. VP of Strategy & Corp. Devel.
Comp: $1.26M

Mr. Larry L. Wood (Age 56)
Corp. VP of Transcatheter Aortic Valve Replacement
Comp: $1.31M

Mr. Jean-Luc Lemercier (Age 65)
Corp. VP of Europe, Middle East, Africa, Canada & Latin America
Comp: $1.43M

Dr. Todd J. Brinton
Corp. VP of Advanced Technology & Chief Scientific Officer

Mark Wilterding
VP of Investor Relations

Mr. Arnold A. Pinkston (Age 63)
Corp. VP & Gen. Counsel

Mr. Dirksen J. Lehman
Corp. VP of Public Affairs

Ms. Christine Z. McCauley (Age 57)
Corp. VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EW Stock - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?: 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EW shares.
View EW analyst ratings or view top-rated stocks.
What is Edwards Lifesciences' stock price forecast for 2022?: 20 Wall Street research analysts have issued 12-month price objectives for Edwards Lifesciences' shares. Their EW share price forecasts range from $106.00 to $144.00. On average, they anticipate the company's stock price to reach $125.50 in the next year. This suggests a possible upside of 51.9% from the stock's current price.
View analysts price targets for EW or view top-rated stocks among Wall Street analysts.
How have EW shares performed in 2022?: Edwards Lifesciences' stock was trading at $129.55 at the beginning of 2022. Since then, EW shares have decreased by 36.2% and is now trading at $82.63.
View the best growth stocks for 2022 here.
Are investors shorting Edwards Lifesciences?: Edwards Lifesciences saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 6,540,000 shares, an increase of 77.7% from the August 31st total of 3,680,000 shares. Based on an average daily volume of 2,570,000 shares, the days-to-cover ratio is currently 2.5 days. Currently, 1.1% of the company's stock are short sold.
View Edwards Lifesciences' Short Interest.
When is Edwards Lifesciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our EW earnings forecast.
How were Edwards Lifesciences' earnings last quarter?: Edwards Lifesciences Co. (NYSE:EW) posted its quarterly earnings results on Thursday, July, 28th. The medical research company reported $0.63 earnings per share for the quarter, meeting analysts' consensus estimates of $0.63. The medical research company earned $1.37 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 27.18% and a trailing twelve-month return on equity of 24.77%. The firm's revenue was down .2% on a year-over-year basis. During the same period last year, the firm earned $0.64 EPS.
Read the conference call transcript.
When did Edwards Lifesciences' stock split?: Edwards Lifesciences's stock split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were distributed to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.
What guidance has Edwards Lifesciences issued on next quarter's earnings?: Edwards Lifesciences updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of $2.50-$2.50 for the period, compared to the consensus EPS estimate of $2.56. The company issued revenue guidance of $5.35 billion-$5.55 billion, compared to the consensus revenue estimate of $5.71 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?: 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.
What other stocks do shareholders of Edwards Lifesciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).
What is Edwards Lifesciences' stock symbol?: Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."
How do I buy shares of Edwards Lifesciences?: Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Edwards Lifesciences' stock price today?: One share of EW stock can currently be purchased for approximately $82.63.
How much money does Edwards Lifesciences make?: Edwards Lifesciences (NYSE:EW) has a market capitalization of $51.23 billion and generates $5.23 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.31 on an earnings per share basis.
How many employees does Edwards Lifesciences have?: The company employs 15,700 workers across the globe.
Does Edwards Lifesciences have any subsidiaries?: The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
How can I contact Edwards Lifesciences?: Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.

This page (NYSE:EW) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Edwards Lifesciences - EW Stock Forecast, Price & News

Edwards Lifesciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows